Results 21 to 30 of about 18,344 (221)

Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol

open access: yesScientific Reports, 2017
Mitochondrial dysfunction is associated with numerous acute and chronic degenerative diseases. The beta-2 adrenergic receptor (β2AR) agonist formoterol induces mitochondrial biogenesis (MB), but other β2AR agonists, such as clenbuterol, do not. We sought
Robert B. Cameron   +3 more
doaj   +1 more source

Increased FKBP51 in induced sputum cells of chronic obstructive pulmonary disease patients after therapy

open access: yesEuropean Journal of Medical Research, 2009
Objective Immunophilin FKBP51 assists polypeptide folding, participates in glucocorticoid actions and may play a role in glucocorticoid resistance. FKBP51 is altered in patients with asthma, but its role in chronic obstructive pulmonary disease (COPD ...
Holownia A   +4 more
doaj   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

open access: yes, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers   +27 more
core   +2 more sources

Formoterol, a β2-adrenoreceptor agonist, induces mitochondrial biogenesis and promotes cognitive recovery after traumatic brain injury

open access: yesNeurobiology of Disease, 2020
Traumatic brain injury (TBI) leads to acute necrosis at the site of injury followed by a sequence of secondary events lasting from hours to weeks and often years.
Hemendra J. Vekaria   +7 more
doaj   +1 more source

Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children (Review) [PDF]

open access: yes, 2009
Background Traditionally inhaled treatment for asthma has been considered as preventer and reliever therapy. The combination of formoterol and budesonide in a single inhaler introduces the possibility of using a single inhaler for both prevention and ...
Adams   +50 more
core   +1 more source

Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. [PDF]

open access: yes, 2013
BACKGROUND: Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest tightness and cough. Treatment with inhaled steroids and bronchodilators often results in good control of symptoms, prevention of ...
Ferrara, G   +3 more
core   +1 more source

Fixed-dose combination fluticasone/formoterol for asthma treatment in a real-world setting: meta-analysis of exacerbation rates and asthma control

open access: yesEuropean Clinical Respiratory Journal, 2023
Background: Treatment guidelines for asthma management are derived almost exclusively from the results of controlled clinical trials undertaken in carefully selected patient populations; meaning that their outcomes may not reflect the true performance of
Alberto Papi   +7 more
doaj   +1 more source

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. [PDF]

open access: yes, 2014
BACKGROUND: Inhaled corticosteroids (ICS) are anti-inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive pulmonary disease (COPD) and repeated exacerbations.
Agarwal   +163 more
core   +1 more source

Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

open access: yesBMC Pulmonary Medicine, 2011
Background This study evaluated the efficacy and safety of the long-acting β2-agonist formoterol in patients with moderate-to-severe COPD. Methods This double-blind, placebo-controlled, parallel-group, multinational phase III study randomized patients ...
Bogdan Miron A   +5 more
doaj   +1 more source

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma [PDF]

open access: yes, 2011
Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta2-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered ...
Adams   +207 more
core   +1 more source

Home - About - Disclaimer - Privacy